Global Dendritic Cell Cancer Vaccine Market Dosage Price & Clinical Trials Outlook 2024

  • ID: 4481614
  • Report
  • Region: Global
  • 255 Pages
  • Kuick Research
15 % OFF
until Jan 15th 2019
1 of 5

FEATURED COMPANIES

  • 3M Company
  • Batavia Bioservices
  • DanDrit Biotech
  • Elios Therapeutics
  • Kiromic
  • Northwest Biotherapeutics
  • MORE

“Global Dendritic Cell Cancer Vaccine Market Dosage Price & Clinical Trials Outlook 2024” Report Highlight:

  • Role of Dendritic Cells in Immune System & Cancer
  • Price & Dosage Analysis  of Marketed Dendritic Cell Cancer Vaccine
  • Availability & Efficacy Analysis
  • Marketed Dendritic Cell Cancer Vaccines Clinical Insight: 3 Vaccines
  • Comparative Assessment of Provenge v/s other Key Therapeutics
  • Dendritic Cell Cancer Vaccines Clinical Pipeline by Company, Indication & Phase: 63 Vaccines

Conventional therapies like surgery, radiotherapy and chemotherapies are the initial approaches for treating cancer. However, several researchers indicated that these conventional therapies are unable to treat cancer from its root cause and also produce many adverse effects thus, cannot be considered as a future of cancer therapy. Further findings demonstrated that cancer cells directly affect T-cells of the immune system and suppresses the immune activity against it resulting in uninhibited growth of cancer cells. Such incidences triggered the era of modern cancer therapy.

Advances in cellular technologies initiated the research towards exploitation of immune cells for the development of advanced vaccines for treating cancer. One of the cells which are found to be the most attractive target for developing therapeutic vaccines are Dendritic cells as they have the ability to present multiple antigens which are most suited to be a therapy for a multi-cause disease like cancer.

Dendritic cell cancer vaccines have gained significant importance in the market with the approval of first dendritic cell cancer vaccine for metastatic prostate cancer called Provenge. Provenge was approved almost a decade ago and has generated high revenues for the pharmaceutical companies. Dendritic cell vaccines became one of the most promising approaches as it works by boosting up the immune system which in turn will cause no or minimal side effects. Furthermore, cancer is disease with multiple causes and risk factors; researchers stated that instead of preventive vaccines, effective therapeutic vaccines can be developed to treat cancer.

Followed by the approval of Provenge, several similar products were developed for other indications in different regions of the world including CreaVax in South Korea for prostate and kidney cancer and Apceden in India for multiple solid tumors. Additionally, a wide range of dendritic cell vaccines entered in different phases of clinical pipeline such as Vaccell in Japan, TAP Cells in Chile, MelCancerVac in North America and Rocapuldencel-T in US etc. All these dendritic cell cancer vaccines are expected to be approved and commercialized and enhance the Global Dendritic cell vaccine market.

Dendritic cell vaccine is the fastest growing segment of cancer vaccine market with other classes of vaccine like peptide vaccines, HPV vaccine, HBV vaccines etc. Dendritic cell vaccines are more specific for treating cancer while others are limited to the treatment of chronic conditions which can cause cancer. Additionally, development of dendritic cell vaccine has been one of the fastest growing sectors amongst all and has resulted in a strong clinical pipeline with more than 60 products in different phases of clinical trials.

Moreover dendritic cell vaccines are unique of its kind which is specifically approved for advanced stages of cancer. Lack of availability of targeted therapies for advance stage of diseases, highly unmet medical needs of metastatic cancer patients indicates exponential rise in the demand for dendritic cell cancer vaccines. Furthermore, commercial successes of Provenge which is available in more than 35 countries; CreaVax in South Korea due to large target patient base has resulted in significant growth of the market.

Increasing prevalence of cancer around the globe will fuel the commercial success of unique dendritic cell vaccines. For instance, in 2018 more than 70000 and 120000 people are expected to be affected by renal cell carcinoma in US and Europe respectively which will result in great market success of Rocapuldencel-T in the coming future. Additionally, nearly 1 Million new incidences of cancer are expected to occur in Japan in 2018 which will fuel the dendritic cell cancer vaccine market in this region.

Moreover, dendritic cell vaccines are considered to be the future of cancer therapy. With the advancement in technology and better understanding of cancer cells, dendritic cells can be used as a preventive measure in the coming future. Additionally, dendritic cell cancer vaccines are one of the safest methods to treat cancer as they boost patient’s own immune system by presenting and activating specific antigens at the tumor site. Additionally, presence of a wide range of antigens in human immune system and cancer cells provides opportunities for the development of a wide range of unique products.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3M Company
  • Batavia Bioservices
  • DanDrit Biotech
  • Elios Therapeutics
  • Kiromic
  • Northwest Biotherapeutics
  • MORE

1. Prologue to Dendritic Cell Cancer Vaccine
1.1 Historical Overview of Dendritic Cell Cancer Vaccine
1.2 Dendritic Cell Vaccines: A Revolutionary Cancer Therapy

2. Role of Dendritic Cells in Immune System & Cancer
2.1 Dendritic Cell: Integral Part of Human Immune System
2.2 Effects of Cancer on Dendritic Cell Mediated Immunity

3. Mechanism of Action of Dendritic Cell Cancer Vaccines
3.1 Process Involved in Manufacturing Dendritic Cell Vaccine
3.2 Understanding Working Mechanism of Dendritic Cell Vaccine against Cancer Cells

4. Commercially Approved Dendritic Cell Cancer Vaccine: Efficacy, Availability, Price & Dosage Analysis
4.1 Provenge
4.1.1 Clinical Efficacy
4.1.2 Availability, Dosage & Treatment Schedule
4.1.3 Treatment Cost Analysis
4.1.4 Manufacturing Cost & Market Worth
4.2 Apceden (Apceden-L, Apceden-O, Apceden-C, Apceden-P)
4.2.1 Clinical Efficacy
4.2.2 Availability, Dosage & Treatment Schedule
4.3 CreaVax RCC
4.3.1 Availability, Dosage & Treatment Schedule
4.3.2 Manufacturing Cost Process & Involved Technologies

5. Marketed Dendritic Cell Cancer Vaccines Clinical Insight
5.1 Sipuleucel-T (Provenge)
5.2 Dendritic Cell Vaccine (CreaVax-HCC, CreaVax-PC & CreaVax-RCC)
5.3 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical

6. Promising Candidates in Dendritic Cell Cancer Vaccine in Clinical Pipeline
6.1 CreaVax-HCC, CreavAX-PC, CreaVax-BC
6.2 Rocapuldencel-T
6.3 MelCancerVac
6.4 Apceden (Apceden-GBM, Apceden-RCC)
6.5 Vaccell

7. Comparative Assessment of Provenge v/s other Therapeutics for Prostate Cancer
7.1 Provenge v/s Jevtana
7.1.1 Clinical Efficacy
7.1.2 Treatment Course & Dosage
7.1.3 Therapy Price Analysis
7.2 Provenge v/s Zytiga
7.2.1 Clinical Efficacy
7.2.2 Treatment Course & Dosage
7.2.3 Therapy Price Analysis

8. Dendritic Cell Cancer Vaccine Market Opportunity Regional Analysis
8.1 North America
8.2 India
8.3 South Korea
8.4 Japan

9. Dendritic Cell Cancer Vaccine Combination Therapy with other Cancer Therapies
9.1 Dendritic Cell Cancer Vaccine with Radiotherapy
9.2 Dendritic Cell Cancer Vaccine with Monoclonal Antibodies

10. Global Dendritic Cell Cancer Vaccine Current Market Overview
10.1 Global Dendritic Cell Cancer Vaccine Market Trends
10.2 Global Dendritic Cell Vaccine Market Regional Insight
10.2.1 Scope of Dendritic Cell Vaccine Market by Ongoing Researches & Available Advanced Therapies by Region
10.2.2 Scope of Dendritic Cell Vaccine Market by Investments for from Different Sectors
10.2.3 Scope of Reimbursement of Dendritic Cell Cancer Therapy

11. Promising Future of Dendritic Cell Vaccines in Various Cancer
11.1 Dendritic Cell Vaccine in Stage-III Melanoma
11.2 Dendritic Cell Vaccine in Acute Myeloid Leukemia
11.3 Dendritic Cell Vaccine in Brain Tumor

12. Global Dendritic Cell Cancer Vaccine Market Dynamics
12.1 Favorable Market Parameters
12.2 Market Growth Challenges

13. Global Dendritic Cell Cancer Vaccine Market Future Forecast
13.1 Technical Advancements in Dendritic Cell Cancer Vaccine in Future
13.2 Increase in Prevalence of Cancer Providing a Large Target Patient Base for Dendritic Cell Cancer Vaccine in Future

14. Global Dendritic Cell Cancer Vaccines Clinical Pipeline Overview

15. Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Company, Indication & Phase
15.1 Unknown
15.2 Research
15.3 Preclinical
15.4 Clinical
15.5 Phase-I
15.6 Phase-I/II
15.7 Phase-II
15.8 Phase-II/III
15.9 Phase-III

16. Competitive Landscape
16.1 3M Company
16.2 Activartis
16.3 Argos Therapeutics
16.4 Batavia Bioservices
16.5 Bellicum Pharmaceuticals
16.6 Creagene
16.7 DanDrit Biotech
16.8 DCPrime
16.9 Dendreon Corporation
16.10 Elios Therapeutics
16.11 ImmunoCellular Therapeutics
16.12 Immunicum
16.13 Kiromic
16.14 Medigene
16.15 Merck
16.16 Northwest Biotherapeutics
16.17 Glaxo Smith Kline
16.18 ImmunoCellular Therapeutics
16.19 SOTIO
16.20 Tella Incorporation
16.21 Theravectys
16.22 Vaxil BioTherapeutics

List of Figures:
Figure 1-1: Milestones in the History of Dendritic Cell Cancer Vaccine Development
Figure 2-1: Dendritic Cell in Human Immune System
Figure 2-2: Effects of Tumor Cell in Dendritic Cell Dysfunction Leading to Tumor Progression
Figure 3-1: Process of Harvesting Dendritic Cell to Develop Vaccines
Figure 3-2: General Mechanism of Action of Dendritic Cell Vaccine
Figure 4-1:  Provenge: Efficacy on the Basis of Clinical Trials
Figure 4-2: Provenge – Number of Autologous CD54+ Activated Cells (Million)
Figure 4-3: Provenge – Dosage Administration (Minutes)
Figure 4-4: Provenge - Average Duration of Therapy
Figure 4-5: Provenge - Therapy Cost Analysis (US$/Infusion), 2018
Figure 4-6: Provenge – Average Cost (US$/Patient), 2018
Figure 4-7: Provenge – Therapy Cost Analysis (US$/Treatment Course), 2018
Figure 4 8: Provenge – Company’s Expenditure in Drug Development & Therapy Market Value (US$ Billion)
Figure 4-9: Apceden – Median Progression-Free Survival in Patients with Solid Tumors (Number of Months), 2018
Figure 4-10: Apceden – Median Progression Free Survival in Patients with Progressive Solid Tumors (Number of Months), 2018
Figure 4-11: Apceden v/s Provenge – Adverse Side Effects (%), 2018
Figure 4-12: Apceden – Availability of Vial & Vials Required in Apceden Therapy, 2018
Figure 4-13: Apceden – Intervals Between Multiple Doses of Treatment
Figure 4-14: CreaVax RCC – Approval Analysis by Phase (Year)
Figure 4-15: CreaVax RCC – Treatment Course Duration (Weeks), 2018
Figure 4-16: CreaVax RCC – Vial Composition Analysis (mL/Dose & Number of Cells/Dose), 2018
Figure 4-17: South Korea - CreaVax RCC Patent Cost (US$)
Figure 4-18: South Korea – Pharmaceutical Compositions comprising Dendritic Cell Patent Cost (US$)
Figure 7-1: Provenge v/s Jevtana – Median Progression Free Survival (Months)
Figure 7-2: Provenge v/s Jevtana – Overall Survival (Months)
Figure 7-3: Provenge v/s Jevtana – Discontinuation of Treatment in Patients due to Adverse Effects (%)
Figure 7-4: Provenge v/s Jevtana – Average Treatment Cycles in Complete Therapy (By Number)
Figure 7-5: Provenge v/s Jevtana – Price Analysis (US$/Unit), 2018
Figure 7-6: Provenge v/s Jevtana – Price Analysis (US$/Infusion), 2018
Figure 7-7: Provenge v/s Jevtana – Average Treatment Cost Analysis (US$), 2018
Figure 7-8: Provenge v/s Zytiga – Median Progression Free Survival (Months)
Figure 7-9: Provenge v/s Zytiga – Therapy Cost Analysis (US$), 2018
Figure 8-1: Global – Rocapuldencel-T Market Opportunity Analysis by Epidemiology of Renal Cell Carcinoma (Number of patients), 2018
Figure 8-2: India – Average Lung Cancer Prevalence per Year
Figure 8-3: India – Lung Cancer Prevalence by Stage (%), 2018
Figure 8-4: India – Apceden Market Opportunity by Epidemiology of Lung Cancer (Number of Patients), 2014-2018
Figure 8-5: India – Apceden Market Opportunity by Epidemiology of Ovarian Cancer (Number of Patients), 2014-2018
Figure 8-6: India – Apceden Market Opportunity by Epidemiology of Colorectal Cancer (Number of Patients), 2014-2018
Figure 8-7: India – Apceden Market Opportunity by Epidemiology of Prostate Cancer (Number of Patients), 2014-2018
Figure 8-8: South Korea – Renal Cell Carcinoma Population by Stage of Cancer, (%), 2018
Figure 8-9: South Korea – CreaVax RCC Market Opportunity by Renal Cancer Epidemiology (Number of Patients), 2014-2018
Figure 8-10: South Korea – Renal Cell Carcinoma Prevalence in Male Population by Number, 2014-2018
Figure 8-11: South Korea - Renal Cell Carcinoma Prevalence in Female Population by Number, 2014-2018
Figure 8-12: South Korea – Renal Cancer Prevalence by Gender, 2018
Figure 8-13: Japan – Epidemiology of Cancer by Gender (%), 2018
Figure 8-14: Japan – Epidemiology of Cancer (Number of Patients), 2018
Figure 8-15: Japan – Vaccell Market Opportunity by Epidemiology of Pancreatic Cancer by Gender (%), 2018
Figure 8-16: Japan – Vaccell market Opportunity by Epidemiology of Pancreatic Cancer (Number of Patients), 2018
Figure 8-17: Japan – Vaccell Market Opportunity by Epidemiology of Gall Bladder & Biliary Cancer by Gender (%), 2018
Figure 8-18: Japan – Vaccell Market Opportunity by Epidemiology of Gall Bladder & Biliary Cancer (Number of Patients), 2018
Figure 8 19: Japan – Vaccell Potential Patient Base by New Incidences, 2018
Figure 10-1: Global - Scope of Dendritic Cell Cancer Therapy Market by Ongoing Researches
Figure 10-2: Global – Scope of Dendritic Cell Cancer Therapy Market by Approved Advanced Therapies
Figure 10-3: Global – Scope of Dendritic Cell Vaccine Cancer Therapy Market by Later Phase Clinical Trials
Figure 10-4: Global – Number of Advanced Cancer Therapy Research Studies Funded by Non-Profit Organization
Figure 12-1: Factors Favoring Global Dendritic Cell Cancer Vaccine Market
Figure 13-1: Global – Dendritic Cell Cancer Vaccine Market Opportunity by Prevalence of Cancer (%)
Figure 14-1: Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Phase (%), 2018 till 2024
Figure 14-2: Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 14-3: Global Dendritic Cell Cancer Vaccines Suspended in Clinical Pipeline by Phase (%), 2018 till 2024
Figure 14-4: Global Dendritic Cell Cancer Vaccines Suspended in Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 14-5: Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Region/Country (%), 2018 till 2024
Figure 14-6: Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Company (%), 2018 till 2024
Figure 16-1: Argos Therapeutics- Clinical Pipeline
Figure 16-2: Bellicum Pharmaceuticals Clinical Pipeline
Figure 16-3: DCPrime Clinical Pipeline
Figure 16-4: ImmunoCellular Therapeutics Clinical Pipeline
Figure 16-5: Immunicum Clinical Pipeline
Figure 16-6: Medigene Clinical Pipeline
Figure 16-7: Northwest Biotherapeutics Clinical Pipeline
Figure 16-8: SOTIO Clinical Pipeline

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 3M Company
  • Activartis
  • Argos Therapeutics
  • Batavia Bioservices
  • Bellicum Pharmaceuticals
  • Creagene
  • DCPrime
  • DanDrit Biotech
  • Dendreon Corporation
  • Elios Therapeutics
  • Glaxo Smith Kline
  • Immunicum
  • ImmunoCellular Therapeutics
  • ImmunoCellular Therapeutics
  • Kiromic
  • Medigene
  • Merck
  • Northwest Biotherapeutics
  • SOTIO
  • Tella Incorporation
  • Theravectys
  • Vaxil BioTherapeutics
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll